Sangamo’s Fabry Gene Therapy Can Rely On 25-Person Registration Trial After US FDA Meeting

With a PRIME designation also in hand for isaralgagene civaparvovec, Sangamo still needs to secure a partner before beginning its pivotal trial, which importantly will not have to include a head-to-head comparison with enzyme replacement therapies.